NFE2L2 and esophageal squamous cell carcinoma: A recent study analyzed the whole genomic, epigenomic, transcriptomic, and proteomic data of 155 cases of ESCC and led to the classification of the following four subtypes: cell cycle pathway activation (25.2%), NRF2 oncogenic activation (24.5%), immune suppression (19.3%), and immune modulation (31.0%) [54].